Current Report Filing (8-k)
March 21 2019 - 10:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 21, 2019
Heyu Biological Technology Corporation
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay Business
Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip
Code)
Registrant’s telephone number, including
area code:
(86) 158 5924 0902
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01
|
Entry into a Material Definitive Agreement
|
On March 15, 2019, Heyu Biological Technology
Corporation, a Nevada corporation (the “Company”), with the approval of its Board of Directors, entered into a Share
Cancellation Agreement (the “Share Cancellation Agreement”) with Mr. Ban Siong Ang, the President, Chief Executive
Officer, and Chairman of the Board of Directors of the Company (“Mr. Ang”). Pursuant to the Share Cancellation Agreement,
the Company and Mr. Ang agreed to cancel 109,006,861 shares of common stock of the Company previously issued to Mr. Ang.
The foregoing description of the terms of the
Share Cancellation Agreement and the transaction contemplated thereby does not purport to be complete and is subject to, and qualified
in its entirety by, the full text of the Share Cancellation Agreement, which is attached hereto as Exhibit 10.1.
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Heyu Biological Technology Corporation
|
|
|
|
|
By:
|
/s/
Ban Siong Ang
|
|
Name:
|
Ban Siong Ang
|
|
Title:
|
Chief Executive Officer
|
|
|
|
|
Dated:
|
March 21, 2019
|
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Sep 2023 to Sep 2024